The Effect of Dilution with 10% Dextrose Solution on the Potency of Botulinum Toxin A

  • Ham, Jong Wook (Department of Orthodontics and Cosmetic Dentistry, Dr. Ham's Dental and Botulinum Toxin Clinic) ;
  • Kwon, Jeong-Seung (Department of Orofacial Pain and Oral Medicine, Yonsei Dental Hospital, Yonsei University College of Dentistry) ;
  • Cho, Eunae Sandra (Department of Oral Pathology, Oral Cancer Research Institute, Yonsei University College of Dentistry) ;
  • Choi, Jong Hoon (Department of Orofacial Pain and Oral Medicine, Yonsei Dental Hospital, Yonsei University College of Dentistry)
  • Received : 2019.01.18
  • Accepted : 2019.02.02
  • Published : 2019.03.30


Purpose: The aim of this study was to compare the potency-stabilizing effects of two different diluents of botulinum toxin A (10% dextrose solution and 0.9% saline). Methods: A mouse lethality bioassay was undertaken. Ninety mice were divided into experimental and control groups which received varying dosages in subgroups of 10. The experimental group was injected with botulinum toxin A diluted with 10% dextrose solution and the control group was injected with botulinum toxin A diluted with 0.9% saline. A 72 hours after intraperitoneal injection, the number of dead mice was counted to confirm median lethal dose ($LD_{50}$) of each group. Results: The value of $LD_{50}$ in the experimental group was approximately 0.131 mL (1.31 U) and the value of $LD_{50}$ in the control group was approximately 0.107 mL (1.07 U). The potency preservation rate of the experimental group was estimated to be 93.5% and that of the control group was estimated to be 76.3%. Conclusions: Dilution with 10% dextrose solution displayed less potency loss than 0.9% saline.

GGNGBC_2019_v44n1_11_f0001.png 이미지

Fig. 1. LD50 calculation of control group. Using regression equation Y=8.6999X+4.7389, X is calculated when Y is 5, and anti-LogX (Y=5) is 1.07 U.

GGNGBC_2019_v44n1_11_f0002.png 이미지

Fig. 2. LD50 calculation of experimental group. Using regression equation Y=7.4655X+4.1243, X is calculated when Y is 5, and anti- LogX (Y=5) is 1.31 U.

Table 1. Mortality rate after botulinum toxin A injection with or without additional dextrose solution injection

GGNGBC_2019_v44n1_11_t0001.png 이미지

Table 2. Number of dead mouse and mortality rate in the control group

GGNGBC_2019_v44n1_11_t0002.png 이미지

Table 3. Conversions for LD50 in the control group

GGNGBC_2019_v44n1_11_t0003.png 이미지

Table 5. Conversions for LD50 in the experimental group

GGNGBC_2019_v44n1_11_t0004.png 이미지

Table 4. Number of dead mice and mortality rate in the experimental group

GGNGBC_2019_v44n1_11_t0005.png 이미지


Supported by : Yonsei University College of Dentistry


  1. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981;79:734-770.
  2. Mclellan K, Das RE, Ekong TA, Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996;34:975-985.
  3. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56:80-99.
  4. Goodnough MC, Johnson EA. Stabilization of botulinum toxin type A during lyophilization. Appl Environ Microbiol 1992;58:3426-3428.
  5. Randhawa MA. Calculation of LD50 values from the method of Miller and Tainter, 1944. J Ayub Med Coll Abbottabad 2009;21:184-185.
  6. Finney DJ. Probit analysis. 2nd ed. Cambridge: Cambridge University Press; 1952.
  7. Ghosh MN. Fundamentals of experimental pharmacology. 2nd ed. Calcutta: Scientific Book Agency; 1984. pp. 187-189.
  8. Garcia A, Fulton JE Jr. Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study. Dermatol Surg 1996;22:39-43.
  9. Gartlan MG, Hoffman HT. Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage. Otolaryngol Head Neck Surg 1993;108:135-140.
  10. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology 1997;48:249-253.
  11. Yun JH, Ham JW, Park JE, Kim CK. Experimental study on the potency-maintaining periods of reconstituted botulinum type A toxin. J Korean Dent Assoc 2005;43:119-125.
  12. Kazim NA, Black EH. Botox: shaken, not stirred. Ophthalmic Plast Reconstr Surg 2008;24:10-12.
  13. Trindade De Almeida AR, Kadunc BV, Di Chiacchio N, Neto DR. Foam during reconstitution does not affect the potency of botulinum toxin type A. Dermatol Surg 2003;29:530-531; discussion 532.
  14. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000;203:1-60.
  15. Pearce LB, Borodic GE, First ER, MacCallum RD. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994;128:69-77.
  16. Cichon JV Jr, McCaffrey TV, Litchy WJ, Knops JL. The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Laryngoscope 1995;105:144-148.
  17. Ekong TA, Feavers IM, Sesardic D. Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 1997;143:3337-3347.
  18. Sesardic D, McLellan K, Ekong TA, Das RG. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmacol Toxicol 1996;78:283-288.
  19. Kim JY, Kim ST, Cho SW, Jung HS, Park KT, Son HK. Growth effects of botulinum toxin type A injected into masseter muscle on a developing rat mandible. Oral Dis 2008;14:626-632.